Miromatrix Medical (NASDAQ:MIRO – Get Rating) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
This is a breakdown of recent ratings and recommmendations for Miromatrix Medical and Tarsus Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Miromatrix Medical currently has a consensus target price of $9.00, indicating a potential upside of 243.51%. Tarsus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 174.43%. Given Miromatrix Medical’s higher possible upside, analysts clearly believe Miromatrix Medical is more favorable than Tarsus Pharmaceuticals.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Miromatrix Medical||$30,000.00||1,825.27||-$14.67 million||($1.39)||-1.88|
|Tarsus Pharmaceuticals||$57.03 million||6.99||-$13.83 million||($2.78)||-5.37|
Tarsus Pharmaceuticals has higher revenue and earnings than Miromatrix Medical. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Miromatrix Medical, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Miromatrix Medical has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
This table compares Miromatrix Medical and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
16.9% of Miromatrix Medical shares are owned by institutional investors. Comparatively, 76.8% of Tarsus Pharmaceuticals shares are owned by institutional investors. 4.9% of Miromatrix Medical shares are owned by company insiders. Comparatively, 24.7% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Tarsus Pharmaceuticals beats Miromatrix Medical on 9 of the 13 factors compared between the two stocks.
About Miromatrix Medical
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.